Defence Therapeutics Inc. DTC.F Stock
Defence Therapeutics Inc. Price Chart
Defence Therapeutics Inc. DTC.F Financial and Trading Overview
| Defence Therapeutics Inc. stock price | 0.79 EUR |
| Previous Close | 1.79 EUR |
| Open | 1.82 EUR |
| Bid | 1.8 EUR x N/A |
| Ask | 1.89 EUR x N/A |
| Day's Range | 1.82 - 1.82 EUR |
| 52 Week Range | 1.03 - 3.41 EUR |
| Volume | 100 EUR |
| Avg. Volume | 2.85K EUR |
| Market Cap | 83.47M EUR |
| Beta (5Y Monthly) | 2.262995 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.13 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
DTC.F Valuation Measures
| Enterprise Value | 76.08M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 56.875 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Defence Therapeutics Inc. Stock Price History
| Beta (5Y Monthly) | 2.262995 |
| 52-Week Change | 14.56% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.41 EUR |
| 52 Week Low | 1.03 EUR |
| 50-Day Moving Average | 2.13 EUR |
| 200-Day Moving Average | 1.91 EUR |
DTC.F Share Statistics
| Avg. Volume (3 month) | 2.85K EUR |
| Avg. Daily Volume (10-Days) | 1.44K EUR |
| Shares Outstanding | 43.68M |
| Float | 41.55M |
| Short Ratio | N/A |
| % Held by Insiders | 5.10% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -174.25% |
| Return on Equity (ttm) | -506.97% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -7212333 EUR |
| Diluted EPS (ttm) | -0.13 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.88M EUR |
| Total Cash Per Share (mrq) | 0.07 EUR |
| Total Debt (mrq) | 1.64M EUR |
| Total Debt/Equity (mrq) | 123.41 EUR |
| Current Ratio (mrq) | 17.423 |
| Book Value Per Share (mrq) | 0.032 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6779771 EUR |
| Levered Free Cash Flow (ttm) | -4222312 EUR |
Profile of Defence Therapeutics Inc.
| Country | Germany |
| State | BC |
| City | Vancouver |
| Address | 1680 – 200 Burrard Street |
| ZIP | V6C 3L6 |
| Phone | N/A |
| Website | https://defencetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Q&A For Defence Therapeutics Inc. Stock
What is a current DTC.F stock price?
Defence Therapeutics Inc. DTC.F stock price today per share is 0.79 EUR.
How to purchase Defence Therapeutics Inc. stock?
You can buy DTC.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Defence Therapeutics Inc.?
The stock symbol or ticker of Defence Therapeutics Inc. is DTC.F.
Which industry does the Defence Therapeutics Inc. company belong to?
The Defence Therapeutics Inc. industry is Biotechnology.
How many shares does Defence Therapeutics Inc. have in circulation?
The max supply of Defence Therapeutics Inc. shares is 45.44M.
What is Defence Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Defence Therapeutics Inc. PE Ratio is now.
What was Defence Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Defence Therapeutics Inc. EPS is -0.13 EUR over the trailing 12 months.
Which sector does the Defence Therapeutics Inc. company belong to?
The Defence Therapeutics Inc. sector is Healthcare.